Victor Tapson
Pulmonary Disease · Los Angeles, CANPI 1275693400
Payments from drug & device makers
Across 340 payments — averaging $2737.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$213K
- Janssen Research & Development, LLC$172K
- Johnson & Johnson$165K
- Merck$129K
- E.r. Squibb & Sons, L.L.C.$55K
- United Therapeutics Corporation$53K
- plus $144K from 19 others
Across 2 payments — averaging $2280.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 3 | $212,990 |
| Janssen Research & Development, LLC | 24 | $171,937 |
| Johnson & Johnson | 121 | $164,882 |
| Merck | 7 | $129,254 |
| E.r. Squibb & Sons, L.L.C. | 7 | $55,222 |
| United Therapeutics Corporation | 47 | $52,724 |
| Daiichi Sankyo Inc. | 20 | $49,386 |
| Actelion Pharmaceuticals, Ltd | 24 | $35,566 |
| Boston Scientific | 2 | $16,969 |
| Actelion Pharmaceuticals US, Inc. | 11 | $13,121 |
| Pfizer | 4 | $6,866 |
| Biocompatibles, Inc. | 6 | $6,609 |
| Inari Medical, Inc. | 38 | $6,401 |
| EKOS Corporation | 4 | $4,595 |
| Janssen Scientific Affairs, LLC | 2 | $1,800 |
| Stryker | 5 | $691 |
| Angiodynamics, Inc. | 1 | $597 |
| Inquis Medical, Inc. | 3 | $249 |
| Imperative Care, Inc | 1 | $195 |
| Jubilant Draximage Inc. | 2 | $190 |
| Viz.ai, Inc. | 1 | $124 |
| AstraZeneca | 1 | $96 |
| Sandoz | 3 | $56 |
| Gilead | 2 | $47 |
| Genentech USA, Inc. | 1 | $38 |
How this compares
$930,602 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- John BelperioLos Angeles$905K
- Sivagini GaneshLos Angeles$816K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.